Nephrology Conferences
Advertisement
Interim analysis from the APPLAUSE-IgAN trial found favorable results for the use of iptacopan in IgAN.
A super-learner strategy gave accurate risk predictions of kidney failure and death for people with moderate to severe CKD.
Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for IgAN treatment.
Researchers uncovered clinical and economic of the Kidney BEAM physical activity digital health intervention for CKD.
Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan.
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
A simulation model predicts a dramatic increase in the impact of chronic kidney disease in the next 10 years.
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Results of a study evaluating the prevalence of common comorbid conditions in patients with ADPKD.
Clinical development models for polycystic kidney disease remain challenging.
Early diagnosis of CKD and active management can slow progression and improve outcomes.
Using antihypertensive medication in patients with persistent treatment-resistant hypertension concurrent with CKD.
Patients receiving maintenance hemodialysis who develop anemia are commonly treated with erythropoiesis-stimulating agents.
Patients with end-stage kidney disease with anemia are commonly treated with recombinant human erythropoietin.
Examining whether administration of patiromer would reduce the number of significant arrhythmia events.
Training an artificial intelligence algorithm that can detect hyperkalemia from the surface electrocardiogram.
The pooled proportion of all serious adverse effects related to remdesivir was 2.9%.
Results of an analysis to characterize the sequelae of COVID-19 infection among kidney transplant recipients.
Albuminuria is a strong determinant of kidney and cardiovascular risk in those with and without type 2 diabetes.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.